

FOR IMMEDIATE RELEASE

Contacts:

Steve Parkinson
President and CEO
Lakewood-Amedex Inc.
(941) 359 0510 / 225 5859
sparkinson@lakewoodamedex.com

Paul DiTullio
Vice President
Lakewood-Amedex, Inc.
(941) 225-2516
pditullio@lakewoodamedex.com

**LAKEWOOD-AMEDEX ANNOUNCES EXPANDED RESEARCH COLLABORATION
WITH THE UNIVERSITY OF JYVÄSKYLÄ FOLLOWING PROMISING RESULTS
DEMONSTRATING BISPHOSPHOCIN™ ACTIVITY AGAINST *BORRELIA
BURGDORFERI***

Sarasota, Florida, March 12, 2015 – Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that it has expanded upon a research collaboration with Dr. Leona Gilbert at the Department of Biological and Environmental Sciences of the University of Jyväskylä, Finland to further characterize the activity of bisphosphocins™ against *Borrelia burgdorferi*. *B. burgdorferi* is the pathogen responsible for Lyme disease, a chronic multisystem difficult to treat debilitating disease that can have long term health consequences for patients. The reported patient population is large and growing rapidly. The collaboration has been established to build on initial findings demonstrating the effectiveness of bisphosphocin™ Nu-3 in killing multiple life forms of *B. burgdorferi*. The research collaboration is intended to fully determine the mechanism of action, characterize the bactericidal activity against the various forms of *B. burgdorferi*, and select a lead bisphosphocin™ candidate for potential pre-clinical development.

About Lakewood-Amedex, Inc.

Lakewood-Amedex is a privately held clinical stage biopharmaceutical company developing a broad portfolio of innovative novel-approach anti-infective products in the treatment of serious infectious diseases, improving patient outcomes and significantly reducing the threat posed by antibiotic-resistant

bacterial strains like MRSA, VRE, NDM-1, and biofilm strains. The Company's products and technology are covered by an extensive patent portfolio consisting of 74 issued and 13 pending patents. The Company's lead product, Nu-3, a first-in-class antimicrobial, is being developed as a treatment for bacterial and fungal infections. Lakewood-Amedex is also developing orally available 'gene silencing' mRNA therapeutics for the treatment of various viral indications, oncology applications, inflammatory conditions and other chronic human diseases.

About University of Jyväskylä.

The University of Jyväskylä, Finland, is a nationally and internationally significant research university and an expert on education that focuses on human and natural sciences. The University of Jyväskylä has 15,000 degree students, and the number of staff is 2,600. The Department of Biological and Environmental Sciences offers high-quality teaching and is founded on excellent research activities. Dr. Leona Gilbert Research Group, a part of Cell and Molecular Biology in the Department of Biological and Environmental Science, provides teaching and undertakes research in a field bordering with biochemistry, chemistry, biotechnology, molecular and cell biology and nano-science. The main focus of Dr. Leona Gilbert's Research Group is to "Understanding Microbial Effectors that Contribute to Chronic Diseases". This research group provides a framework for the analysis of a common adverse viral / bacterial infection and its contribution to chronic autoimmune diseases

This press release contains forward-looking statements that can be identified by terminology such as "expects", "potential", "suggests", "may", "will" or similar expressions. Such forward-looking statements regarding our business, which are not historical facts, are "forward-looking statements" that involve risk and uncertainties, which could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. Actual results may differ materially from statements made as a result of various factors, including, but not limited to sufficiency of cash to fund the Company's planned operations, risk associated with inherent uncertainty of product research and development, risk of protecting proprietary rights and competition. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect the circumstances or events that occur after the date the forward-looking statements are made.